Pharmaceuticals

ITERUM THERAPEUTICS PLC

ITRMF.US released FY2025 Q3 earnings on November 14 Pre-Market (BJT), actual revenue USD 390K, actual EPS USD -0.196

ITRMF.US released FY2024 Q2 earnings on August 5 Pre-Market (BJT), actual revenue USD 0, actual EPS USD -0.3018

ITERUM THERAPEUTICS PLC released FY2024 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4601 (forecast USD --)

ITERUM THERAPEUTICS PLC released FY2025 9 Months earnings on November 14 Pre-Market (EST), actual revenue USD 390K, actual EPS USD -0.5026

ITERUM THERAPEUTICS PLC released FY2024 Semi-Annual earnings on August 5, Pre-Market EST, with actual revenue of USD 0 and EPS of USD -0.7564

ITERUM THERAPEUTICS PLC released FY2025 Q2 earnings on August 5 Pre-Market EST, with actual revenue USD 0 and actual EPS USD -0.1629

ITRMF.US released FY2024 9 Months Earnings on November 14 Pre-Market (BJT), Actual Revenue USD 0, Actual EPS USD -1.066

ITRMF.US released FY2025 Q1 earnings on May 13 Pre-Market (BJT), actual revenue USD 0, actual EPS USD -0.1436

ITERUM THERAPEUTICS PLC released FY2025 Semi-Annual Earnings on August 5, Pre-Market EST, with actual revenue of USD 0 and EPS of USD -0.3079

ITERUM THERAPEUTICS PLC released FY2024 Q3 earnings on November 14 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.304 (forecast USD --)

Phoenix Asia

Sadot

EZGO Tech

Sobr Safe

Backblaze

Everquote

Sterling Infrastructure

Skycorp Solar

3 E Network Tech

Selectquote

ITRM

ITRMF

Antibiotic resistance is escalating, yet investment in new antibiotics is declining. Iterum Therapeutics, after FDA approval for its antibiotic Orlynvah, faced financial struggles and announced plans to cease operations. The market punishes antibiotic developers due to high commercialization costs and low sales, despite the urgent need for new treatments. Policymakers are slow to act, with the U.S. lacking effective solutions like those in the UK and EU. The Pasteur Act aims to incentivize antibiotic development, but without systemic changes, more companies may face bankruptcy, jeopardizing patient care.

Thehill

Iterum Therap

Antibiotic resistance is growing — don't delay new antibiotics

IINN

LABU

SBIO

In Tuesday's after-market session, Iterum Therapeutics (ITRM) saw a significant gain of 37.0%, reaching $0.04, while Inspira Technologies Oxy (IINN) rose 11.01% to $0.5. Other gainers included Profusa (PFSA) up 9.13% to $0.55, and Omeros (OMER) up 7.96% to $11.4. Conversely, ORIC Pharmaceuticals (ORIC) fell 25.1% to $9.49, and BioAtla (BCAB) dropped 18.89% to $0.13. The Q4 earnings reports for several companies were released today, impacting stock movements.

benzinga_article

Inspira Tech OXY

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Profusa

VG Health

ALPS Medical Breakthrough

Omeros

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

12 Health Care Stocks Moving In Tuesday's After-Market Session

VRAX

PEPG

In Tuesday's intraday session, Apellis Pharmaceuticals saw a significant gain of 135.5%, reaching $40.26, with a market cap of $2.1 billion. Other notable gainers included Bullfrog AI Hldgs (+62.85%), Centessa Pharmaceuticals (+44.76%), and Virax Biolabs Group (+29.84%). Conversely, IO Biotech experienced a sharp decline of 73.2%, dropping to $0.05, followed by PepGen (-63.72%) and Iterum Therapeutics (-45.74%). The Q4 earnings reports influenced these movements, with several companies reporting significant changes in stock prices.

Virax Biolabs

iShares US Pharma

Bullfrog AI

PepGen

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM)

Centessa Pharmaceuticals

IO Biotech

Apellis Pharma

iShares Global Healthcare

IO BIOTECH INC

12 Health Care Stocks Moving In Tuesday's Intraday Session

In Tuesday's pre-market session, Apellis Pharmaceuticals saw a significant gain of 138.8%, reaching $40.81, with a market cap of $2.1 billion. Other notable gainers included Virax Biolabs (up 62.43%), Centessa Pharmaceuticals (up 47.49%), and Insight Molecular (up 34.9%). Conversely, PepGen experienced a sharp decline of 48.7%, followed by Iterum Therapeutics (down 32.53%) and Phreesia (down 24.19%). Several companies reported Q4 earnings recently, impacting stock movements.

Insight Molecular Diagnostics

SPDR S&P Health Equip

iShares US Medical Devices

Phreesia

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Iterum Therapeutics has received a notice from Nasdaq regarding the delisting of its ordinary shares due to the withdrawal of its appeal against a previous delisting decision. This decision was made because the company failed to maintain the required minimum bid price of $1.00. Trading will be suspended on April 1, 2026, and a Form 25-NSE will be filed to officially remove the shares from Nasdaq.

TradingView

Iterum Therapeutics Received Notice of Delisting

NBRVF

Keenova Therapeutics plc announced its unaudited financial results for Q4 2025, reporting net sales of $543 million, driven by strong performances in Acthar Gel and XIAFLEX. The company expects a loss from continuing operations between $105 million and $115 million, influenced by merger-related costs. Adjusted EBITDA is projected at $210-$220 million. Keenova anticipates 2026 net sales of $1.94-$2 billion and plans to pursue a NYSE listing in the second half of the year. The company also reported successful trial results for its hammer toe program, moving towards a Phase 3 study.

prnewswire

Nabriva Therapeutics plc

Sernova Corp.

06:30 ETKeenova Announces Unaudited Fourth Quarter 2025 Financial Results

System1 pre-market up 13.67%; Iterum Therap pre-market down 11.79%; Hitek Global Inc. pre-market up 122.25%; Megan pre-market up 47.13%; Oxbridge Re pre-market up 28.96%

Price Alert

System1

Pre-market hot trades in US stocks: System1 up 13.67% in pre-market; Iterum Therap down 11.79% in pre-market

Iterum Therapeutics plc (ITRM) shares surged 140.45% to $0.0883 on Monday following a winding-up petition filed in the High Court in Ireland. The court hearing is scheduled for April 13, 2026, which could lead to the company's dissolution due to limited cash resources and Nasdaq compliance issues. Additionally, the company may withdraw its antibiotic ORLYNVAH from the U.S. market. Recent updates include a rebate agreement expanding access for ORLYNVAH and securing a U.S. patent. The FDA has indicated that further data is needed for ORLYNVAH's approval as a step-down therapy.

Fidelity

What's Going On With Iterum Therapeutics Stock Monday?

ITERUM THERAPEUTICS PLC(ITRMF.US)